233.89 0.00 (0.00%)
After hours: 4:57PM EDT
|Bid||232.52 x 800|
|Ask||233.99 x 1000|
|Day's Range||231.86 - 234.42|
|52 Week Range||216.12 - 388.67|
|Beta (3Y Monthly)||1.62|
|PE Ratio (TTM)||10.11|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MISSISSAUGA, ON , June 13, 2019 /CNW/ - Biogen Canada is pleased to announce that patients in Ontario living with spinal muscular atrophy (SMA) now have broader publicly funded access to SPINRAZA™ (nusinersen), the first and only treatment approved in Canada for SMA.
Data to be presented at the European Congress of Rheumatology (EULAR) 2019 highlight real-world evidence confirming the safety and efficacy of anti-TNF biosimilars and high.
Nasdaq: NITE), a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology.
Biogen Inc. (BIIB) announced today new interim data from the ongoing open-label, pivotal EVOLVE-MS-1 study indicate that the investigational treatment diroximel fumarate was generally well tolerated in people with relapsing multiple sclerosis (MS). Diroximel fumarate, a novel oral fumarate candidate in development with Alkermes plc (ALKS), is under review with the U.S. Food and Drug Administration with a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019.
LOS ANGELES , May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico , Ph.D., initiates coverage on six stocks in the Healthcare ...
Biogen Inc. (BIIB) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Corporation (TRC Capital) to purchase up to 500,000 shares of Biogen’s common stock at a price of $216.25 per share in cash. Biogen does not endorse TRC Capital’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in response to TRC Capital’s offer because the offer is at a price below the current market price for Biogen’s shares and subject to numerous conditions.
Biogen Inc. (BIIB) today announced that The National Institute for Health and Care Excellence (NICE) in the United Kingdom has recommended funding for SPINRAZA (nusinersen) on the National Health Service (NHS). The positive recommendation is for the treatment of infants, children and adults with 5q spinal muscular atrophy (SMA), including pre-symptomatic and symptomatic SMA Types 1, 2 and 3.
WOODCLIFF LAKE, N.J., May 13, 2019 /PRNewswire/ -- The Alzheimer's Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) and the investigational anti-amyloid beta (Ab) protofibril antibody BAN2401, which are currently being evaluated as treatments for early Alzheimer's disease (AD), have been selected by the ACTC as treatments to be evaluated in upcoming clinical studies targeting primary prevention (A3 Study) and secondary prevention (A45 Study) of AD.
Biogen Inc. (BIIB) presented new data illustrating its ongoing commitment to improving care for people living with multiple sclerosis (MS) at the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia (May 4–11). Data support the well-established therapies within Biogen’s leading MS portfolio, TECFIDERA® (dimethyl fumarate) and TYSABRI® (natalizumab).
Treatment with SPINRAZA resulted in clinically meaningful improvements in motor-function and survival in individuals with spinal muscular atrophyTreating pre-symptomatic infants.
Biogen Inc. (BIIB) announced today interim results of a phase 1/2 study of tofersen, an antisense oligonucleotide (ASO) being studied for the potential treatment of amyotrophic lateral sclerosis (ALS) in adults with a confirmed superoxide dismutase 1 (SOD1) mutation. The data will be presented at the American Academy of Neurology Annual Meeting (AAN) in Philadelphia, PA (May 4-10, 2019).
Data demonstrate that pre-symptomatic infants with SMA treated with SPINRAZA® (nusinersen) over three years achieved motor milestones that are more consistent with normal.
Biogen (BIIB) today announced that data from CS2/CS12, an open-label study of the safety and tolerability of SPINRAZA in individuals with later-onset spinal muscular atrophy (SMA), were published in the peer-reviewed journal Neurology, the medical journal of the American Academy of Neurology. The data show that individuals with later-onset SMA, treated with SPINRAZA, regained motor function that had been previously lost and that treatment stabilized their disease activity leading to improvements in activities of daily living.
Biogen (BIIB) today announced the nomination of John R. Chiminski, William A. Hawkins and Jesus B. Mantas to stand for election to the company’s board of directors at its 2019 annual meeting of stockholders, scheduled for June 19, 2019. Mr. Chiminski is Chair of the board and Chief Executive Officer of Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. Mr. Hawkins is a Senior Advisor to EW Healthcare Partners, a life sciences private equity firm, and is the former Chairman and Chief Executive Officer of Medtronic, Inc., a global leader in medical technology.
MISSISSAUGA, ON , April 22, 2019 /CNW/ - Biogen Canada welcomes the decision made by the Government of Saskatchewan allowing patients living with Spinal Muscular Atrophy (SMA) to access SPINRAZA™(nusinersen), the first and only approved medicine in the world to treat the root cause of SMA.
Adults with later-onset spinal muscular atrophy (SMA) who are not being treated show increased rates of hospital admissions, clinical interventions and mortality, indicating an.
NEW YORK, March 26, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Biogen (BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia. “This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience. We are incredibly grateful to all the Alzheimer’s disease patients, their families and the investigators who participated in the trials and contributed greatly to this research,” said Michel Vounatsos, Chief Executive Officer at Biogen.
Biogen (BIIB) today announced that it has entered into a share purchase agreement with FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire the shares of Biogen’s subsidiary, which holds Biogen’s biologics manufacturing operations in Hillerød, Denmark, for up to $890 million in cash, subject to minimum purchase commitment guarantees and other contractual terms.
Biogen to acquire Nightstar Therapeutics for $25.50 per share Nightstar Therapeutics is a gene therapy company focused on developing novel treatments for patients suffering.
Today, CADTH publicly released updated recommendations that could inform provincial jurisdictions’ decisions on the public reimbursement of SPINRAZA (nusinersen), the first and only approved treatment shown to be effective in the treatment of Spinal Muscular Atrophy (SMA).
Biogen Inc. (BIIB) today announced that SPINRAZA (nusinersen) has been approved by the China National Medical Products Association (NMPA) for the treatment of 5q spinal muscular atrophy (SMA), expanding the company’s presence in China. Approximately 95 percent of all SMA cases are 5q SMA, making it the most common form of the disease.
NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Alkermes plc (ALKS) and Biogen Inc. (BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis (MS). The NDA has been assigned a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019. If approved, Biogen intends to market diroximel fumarate under the brand name VUMERITY™, which has been conditionally accepted by the FDA and will be confirmed upon approval.